1. Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 study
- Author
-
Yang, Jin-Ji, Zhou, Jianying, Liu, Si-Yang Maggie, Li, Mingjun, Zhang, Zhiye, Cheng, Ying, Fan, Yun, Pan, Hongming, Wang, Baoqing, Chen, Gongyan, Wang, Ke, Jiang, Liyan, Hu, Yanping, Shi, Jianhua, Dong, Xiaorong, Ding, Cuimin, Liu, Yunpeng, Liu, Zhe, Liao, Wangjun, Li, Wei, Wang, Jun, Yi, Shanyong, Zhao, Qiong, Zang, Aimin, Chen, Yuan, Cui, Jiuwei, Luo, Pengfei, Shen, Xionghu, Sun, Meili, Wang, Changli, Wu, Yi-Long, Wu, Yi-Long, Yang, Jin-Ji, Zhou, Jianying, Liu, Si-Yang Maggie, Li, Mingjun, Zhang, Zhiye, Cheng, Ying, Fan, Yun, Pan, Hongming, Wang, Baoqing, Chen, Gongyan, Wang, Ke, Jiang, Liyan, Hu, Yanping, Shi, Jianhua, Dong, Xiaorong, Ding, Cuimin, Liu, Yunpeng, Liu, Zhe, Liao, Wangjun, Li, Wei, Wang, Jun, Yi, Shanyong, Zhao, Qiong, Zang, Aimin, Chen, Yuan, Cui, Jiuwei, Luo, Pengfei, Shen, Xionghu, Sun, Meili, Wang, Changli, Zhou, Yongchun, Wu, Zhuli, Wang, Xingli, Sun, Juan, Guo, Jiayan, Zheng, Yang, Xiang, Xiao, and Hui, Ai-min
- Abstract
Currently approved targeted treatment for ROS1-rearranged non-small-cell lung cancer (NSCLC) has either inadequate intracranial activity or CNS-related toxicities. We evaluated the efficacy and safety of foritinib, a novel ALK and ROS1 inhibitor, in patients with advanced ROS1-rearranged NSCLC.
- Published
- 2024
- Full Text
- View/download PDF